5752 related articles for article (PubMed ID: 3260134)
21. Immune complexes and complement activation following rupture of intracranial saccular aneurysms.
Ostergaard JR; Kristensen BO; Svehag SE; Teisner B; Miletic T
J Neurosurg; 1987 Jun; 66(6):891-7. PubMed ID: 3494822
[TBL] [Abstract][Full Text] [Related]
22. Complement activation during an active cytomegalovirus infection after renal transplantation: due to circulating immune complexes or alternative pathway activation?
van Son WJ; van der Bij W; Tegzess AM; Anema J; van der Giessen M; van der Hem GK; Marrink J; The TH
Clin Immunol Immunopathol; 1989 Jan; 50(1 Pt 1):109-21. PubMed ID: 2535976
[TBL] [Abstract][Full Text] [Related]
23. Significance of circulating immune complexes in pulmonary tuberculosis.
Samuel AM; Ashtekar MD; Ganatra RD
Clin Exp Immunol; 1984 Nov; 58(2):317-24. PubMed ID: 6437714
[TBL] [Abstract][Full Text] [Related]
24. [Elevated levels of circulating immune complexes -C3d and-C1q as a criterion for acute extraintestinal manifestations of ulcerative colitis].
Sagynbaeva VÉ; Lazebnik LB
Eksp Klin Gastroenterol; 2014; (7):18-24. PubMed ID: 25842401
[TBL] [Abstract][Full Text] [Related]
25. Circulating immune complex levels measured by new ELISA kits utilizing monoclonal anti-C1q and anti-C3d antibodies correlate with clinical activities of SLE but not with those of RA.
Yoshinoya S; Mizoguchi Y; Aotsuka S; Yokohari R; Nishioka K; Miyamoto T
J Clin Lab Immunol; 1992; 38(4):161-73. PubMed ID: 11270517
[TBL] [Abstract][Full Text] [Related]
26. Biochemical classification of circulating immune complexes in human malignant melanoma and hematologic neoplasms.
Queen WD; Bharwani N; Phillips EA; Ruether BA; Phillips TM; Jerry LM
Oncology; 1989; 46(1):14-25. PubMed ID: 2915889
[TBL] [Abstract][Full Text] [Related]
27. Complement activation in infective endocarditis: correlation with extracardiac manifestations and prognosis.
Messias-Reason IJ; Hayashi SY; Nisihara RM; Kirschfink M
Clin Exp Immunol; 2002 Feb; 127(2):310-5. PubMed ID: 11876755
[TBL] [Abstract][Full Text] [Related]
28. Malignant melanoma of the skin: long-term follow-up and time to first recurrence.
Hohnheiser AM; Gefeller O; Göhl J; Schuler G; Hohenberger W; Merkel S
World J Surg; 2011 Mar; 35(3):580-9. PubMed ID: 21125274
[TBL] [Abstract][Full Text] [Related]
29. Immunopathological correlation between mesangial C3d-deposition and C3d-fixing circulating immune complexes in lupus nephritis.
Muso E; Sekita K; Doi T; Kuwahara T; Yoshida H; Tamura T; Kawai C; Hamashima Y
Clin Immunol Immunopathol; 1984 Sep; 32(3):351-8. PubMed ID: 6380844
[TBL] [Abstract][Full Text] [Related]
30. Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes.
Porter GA; Abdalla J; Lu M; Smith S; Montgomery D; Grimm E; Ross MI; Mansfield PF; Gershenwald JE; Lee JE
Ann Surg Oncol; 2001 Mar; 8(2):116-22. PubMed ID: 11258775
[TBL] [Abstract][Full Text] [Related]
31. Prognostic and pathogenetic implications of immune complexes in human cancer.
Salinas FA; Wee KH
Adv Immun Cancer Ther; 1986; 2():189-209. PubMed ID: 2962476
[TBL] [Abstract][Full Text] [Related]
32. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
Koyanagi K; O'Day SJ; Gonzalez R; Lewis K; Robinson WA; Amatruda TT; Wang HJ; Elashoff RM; Takeuchi H; Umetani N; Hoon DS
J Clin Oncol; 2005 Nov; 23(31):8057-64. PubMed ID: 16258104
[TBL] [Abstract][Full Text] [Related]
33. Circulating IgA immune complexes in patients with psoriasis.
Hall RP; Peck GL; Lawley TJ
J Invest Dermatol; 1983 Jun; 80(6):465-8. PubMed ID: 6602187
[TBL] [Abstract][Full Text] [Related]
34. S100 protein serum levels in cutaneous malignant melanoma.
Seregni E; Massaron S; Martinetti A; Illeni MT; Rovini D; Belli F; Agresti R; Greco M; Cascinelli N; Bombardieri E
Oncol Rep; 1998; 5(3):601-4. PubMed ID: 9538159
[TBL] [Abstract][Full Text] [Related]
35. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.
Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN
J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466
[TBL] [Abstract][Full Text] [Related]
36. Circulating immune complexes, complement and complement component levels in childhood Hodgkin's disease.
Brandeis WE; Tan C; Wang Y; Good RA; Day NK
Clin Exp Immunol; 1980 Mar; 39(3):551-61. PubMed ID: 7379328
[TBL] [Abstract][Full Text] [Related]
37. Circulating immune complexes in myelofibrosis.
Hasselbalch H; Nielsen H; Berild D; Kappelgaard E
Scand J Haematol; 1985 Feb; 34(2):177-80. PubMed ID: 3871960
[TBL] [Abstract][Full Text] [Related]
38. Prognostic implications of circulating immune complexes and Pseudomonas aeruginosa-specific antibodies in cystic fibrosis.
Dasgupta MK; Lam J; Döring G; Harley FL; Zuberbuhler P; Lam K; Reichert A; Costerton JW; Dossetor JB
J Clin Lab Immunol; 1987 May; 23(1):25-30. PubMed ID: 3112403
[TBL] [Abstract][Full Text] [Related]
39. Complement C3b receptors on erythrocytes, circulating immune complexes, and complement C3 split products in patients with primary Sjögren's syndrome.
Thomsen BS; Oxholm P; Manthorpe R; Nielsen H
Arthritis Rheum; 1986 Jul; 29(7):857-62. PubMed ID: 2943291
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of plasma C3d and immune complex determinations in the assessment of disease activity of patients with rheumatoid arthritis, systemic lupus erythematosus, and spondylitis ancylopoetica.
Krauledat PB; Krapf FE; Manger B; Kalden JR
Rheumatol Int; 1985; 5(3):97-101. PubMed ID: 3892637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]